nhs healthcare contracts

Pharmacy Procurement Contract - A ranked framework for the supply and delivery of Supply of Dose banded compounded chemotherapy split into 2 lots: Lot 1: High Volume Products - 7 molecules / all brands Lot 2: Low Volume Products - 22 molecules / all brands The ranked framework will be open to the participating Trusts of the South East Pharmacy Procurement Service (SEPPS) as follows: 1. Ashford and St Peters Hospital NHS Foundation Trust 2. Berkshire Healthcare NHS Foundation Trust 3. Buckinghamshire Healthcare NHS Trust 4. Dartford and Gravesham NHS Trust 5. East Kent Hospitals NHS Foundation Trust 6. East Sussex Healthcare NHS Trust 7. Frimley Health NHS Foundation Trust 8. Hampshire and Isle of Wight Healthcare NHS Foundation Trust 9. Hampshire Hospitals NHS Foundation Trust 10. Isle of Wight NHS Trust 11. Kent Community Health NHS Trust 12. Maidstone and Tunbridge Wells NHS Trust 13. Medway NHS Foundation Trust 14. Milton Keynes University Hospital NHS Foundation Trust 15. Oxford Health NHS Foundation Trust 16. Oxford University Hospitals NHS Foundation Trust * 17. Portsmouth Hospitals NHS Trust 18. Queen Victoria Hospitals NHS Foundation Trust 19. Royal Berkshire NHS Foundation Trust 20. Royal Surrey County Hospital NHS Foundation Trust 21. Surrey and Borders Partnership NHS Foundation Trust 22. Surrey and Sussex Healthcare NHS Trust 23. Sussex Community NHS Trust 24. Sussex Partnership NHS Foundation Trust 25. University Hospital Southampton NHS Foundation Trust 26. University Hospitals Sussex NHS Foundation Trust This framework will also be available for use by Trusts in East of England and London regions, but the volumes for these regions have not been included for adjudication as part of the tender process. SEC Trusts can utilise this tender for products or services not covered by the National unlicensed aseptically prepared cytotoxic medicines and Dose banded compounded chemotherapy framework via MPSC. Please note: we did not publish a preliminary market engagement notice (UK2) for the following reasons: - we are not seeking to further develop our requirements or procurement approach. - we have procured similar supply arrangements via the Open procedure and deployed similar conditions of participation and award criteria. These have yielded good results previously. - we have prepared our tender pack (see attached), that detail standard NHS contractual terms which have been found to be acceptable to the supply chain. - we understand the likely suppliers who will be interested but the open notice approach gives opportunity to others looking to enter the Dose banded compounded chemotherapy supply market.

The London Borough of Hammersmith & Fulham (the Council) is inviting suitably qualified and experienced providers to tender for the delivery of School Health & Wellbeing Services 5–19 (25). This procurement supports the delivery of the Healthy Child Programme (HCP) and aims to improve health outcomes for children, young people, and families across the borough. The services will provide support for children aged 5–19 years, and up to 25 for young people with SEND. The contract estimated value is £1,110,000 – £1,260,000 per annum

The Common Services Agency (more commonly known as Public Services Delivery Scotland or PSD Scotland) is undertaking an Open procurement process for a Client-Side Partner(s) to assist the NHS Scotland Business Service Progamme. The Business Services Programme is currently undertaking a procurement process for an integrated ERP system. This Invitation to Tender (ITT) will be used to select an appropriate organisation(s) as a Client-Side Partner who will support the NHSS National Programme Team in implementing the preferred ERP solution with the systems integrator, whilst also supporting on the consequential changes to personnel and the ways in which they work.

This Framework is for the Provision of Spinal implants and associated consumables, including Spinal Biologics / Regenerative Technology, Spinal Power Tools, Consumables and Spinal Capital Equipment

The provision of Drugs which have lost or are shortly to lose exclusivity, namely Eculizumab; Icatibant; Nintedanib; Omalizumab; Tocilizumab

AGH Solutions Ltd, on behalf of Airedale NHS Foundation Trust, intends to procure a contestable works partner associated with the provision of a new 33/11kV electricity connection to support the new hospital development of Airedale General Hospital. The scope will include the design, supply, installation and commissioning of approximately 4.3km of 33kV underground cabling and associated fibre communications infrastructure, all required civil engineering and reinstatement works, the construction and fit out of a new on site 33/11kV primary metering substation, installation of two 15/30MVA transformers, protection and control systems, SCADA integration, earthing, testing, and all related activities necessary to deliver a fully compliant contestable connection up to the defined Point of Connection. The contractor will be required to coordinate with Northern Powergrid and any statutory undertakers as necessary to ensure the delivery of an adoptable, standards compliant asset, the contractor must also hold all appropriate regulatory certificates and registrations aligned to NERS/ENA standards. The Trust expressly reserves the right, in accordance with the provisions of the Procurement Act 2023 and any other applicable legislation, to amend, vary, or otherwise modify the programme of works at any stage. Furthermore, should the scope of the project require expansion to accommodate additional or ancillary works and services necessary to achieve the desired outcome, the Trust may, at its sole discretion, increase the estimated fee by up to 50%. Any such adjustment shall be affected in a manner that is fair, transparent, and compliant with all relevant procurement regulations and statutory requirements. Submissions in response to this PQQ shall be made exclusively via email to (m.needham2@nhs.net) This process is designed to ensure full transparency, traceability, and strict adherence to statutory requirements, including those set out in the Procurement Act 2023. All tender activities will be subject to audit and oversight, thereby upholding the integrity and compliance of the procurement process.

NHS England are seeking specialist external support to deliver a financial improvement programme across AACC through two key approaches: large-scale package-level financial reviews and targeted system deep dives. Please note the following general conditions: • This RFI will help us to refine the requirements, future strategy and understand suppliers potential capabilities in the marketplace. • Should a further competition be undertaken we reserve the right to only invite suppliers who have only initially responded to the RFI • We reserve the right not to proceed with a further competition. • Nothing shall constitute a commitment to ordering unless we undertake a further competition that results in the award of a Call-Off Contract. • Any and all costs associated with the production of such a response either to a RFI or a further competition must be borne by the Supplier. We will not contribute in any way to meeting production costs of any response. • Information contained within this document is confidential and must not be revealed to any third party without prior written consent from us. • No down-selection of Potential Providers will take place as a consequence of any responses or interactions relating to this RFI. • We expect that all responses to this RFI will be provided by Potential Providers in good faith to the best of their ability in the light of information available at the time of their response. • No information provided by a Potential Provider in response to this RFI will be carried forward, used or acknowledged in any way for the purpose of evaluating the Potential Provider, in any subsequent formal procurement process.

Background information The GMC is the regulatory body for doctors, physician associates (PAs) and anaesthesia associates (AAs) in the UK, and among other duties is responsible for managing the register of doctors, PAs and AAs in the UK. In order to practise in the UK, a doctor must be registered and hold a licence to practise. Doctors seeking registration are divided into two broad categories based upon their country of qualification: UK graduates and international medical graduates. Until 12 December 2026 PAs and AAs do not require registration to work in the UK, however until then they are encouraged to obtain registration. Most PAs and AAs seeking registration will have a UK qualification, but there are a few applicants who hold an international qualification. Applicants for registration must satisfy a number of criteria, one of which is that they must hold a registrable qualification. For the purpose of this specification, a registrable qualification is defined as a primary medical qualification or associate qualification which is currently accepted by the GMC for the purpose of applying for registration as a doctor, PA or AA. GMC requires the registrable qualification of all doctors, PAs and AAs to be verified with the applicant’s awarding body before the applicant is granted registration. In the case of UK graduates, there is an established process whereby UK medical schools (for doctors) and UK course providers (for PAs and AAs) proactively share graduation data directly with the GMC; for international applicants, however, each applicant’s registrable qualification is verified by the GMC at the point of application. The GMC invites tender bids for primary source verification (PSV) of the registrable qualifications of international doctors, PAs and AAs at the point of registration. Some international applicants will also require other qualifications to be verified depending on the route they are taking to registration.

IPS has been identified by both the DWP and NHS England as good practice in addressing recovery and unemployment. The Department for Work and Pensions Employment and Disability Strategy indicates that appropriate work is good for physical and mental health and is a major part of ensuring people with health conditions “fulfil their potential and have opportunities to play a full role in society” . Employment is now firmly recognised as a critical component of recovery for people with serious mental illness.

The 11 Midlands Region NHS Integrated Care Boards are inviting suitably qualified suppliers to provide Clinical Waste Collection and Disposal Services from Primary Care waste producing sites, these being General Practice (GPs) and Community Pharmacy (CP) settings across the geographical footprint of each of the 11 Midlands Region NHS Integrated Care Boards as set out in table 1.1 of Document 1 to this opportunity. These 11 ICB Commissioning organisations are separate Contracting Authorities, as listed below: Lot 1 = NHS Birmingham and Solihull ICB Lot 2 = NHS Black Country ICB Lot 3 = NHS Coventry and Warwickshire ICB Lot 4 = NHS Herefordshire and Worcestershire ICB Lot 5 = NHS Staffordshire and Stoke-on-Trent ICB Lot 6 = NHS Shropshire, Telford and Wrekin ICB Lot 7 = NHS Derby and Derbyshire ICB Lot 8 = NHS Nottingham and Nottinghamshire ICB Lot 9 = NHS Lincolnshire ICB Lot 10 = NHS Leicester, Leicestershire and Rutland ICB Lot 11 = NHS Northamptonshire ICB Each of the individual 11 ICBs are looking for a Supplier to deliver a Clinical Waste Collection and Disposal Service within their geographical area that: 1. Understands the importance of this collection service for our Waste Producer who deliver key services to the local population 2. Ensures collections are as scheduled and communicated to the GPs and Community Pharmacies with replacement consumables provided as required to Tier 1 Defined Active Waste Producers, Tier 2 Defined Pending Waste Producers and Tier 3 Undefined Pending Waste Procedures. Definitions of the Waste Provider Tiers are located in Document 5 Specification, section 5 Waste Producer Tiers. 3. Complies with regulatory requirements for safe and sustainable management of healthcare waste 4. Supports a circular economy concept of reducing, recycling and reusing waste 5. Supports the Greener NHS and the carbon reduction target 6. Supports each ICB’s cost reduction target of 50% set out by NHS England The Supplier will be required to demonstrate appropriate capability and infrastructure to enable the delivery of the service. For specific note, the Document 1 sets out the following: Please refer to Document 5 - Schedule 5 Service Specification, paragraph 5.5, which states that each Waste Producer is assigned a tier: Tier 1: Defined/Active Waste Producers Active Waste Producers are defined as Waste Producers which form the majority of the Service Requirements, and the core group of Waste Producers receiving Services. The Supplier will be required to provide Services to all Active Waste Producers from the Services Commencement Date. Tier 2: Defined/Pending Waste Producers “Pending Waste Producers” are defined as Waste Producers which can be defined/detailed but are not Active Waste Producers on the Services Commencement Date because they have other existing arrangements in place. It is intended that these Waste Producers will become Active Waste Producers following during the Term in accordance with Document 5 – Specification and or Document 6 – the Contract. The Service Requirements of Tier 2 Waste Producers will not form part of the Services until such time as the Authority notifies the Supplier that a Tier 2 Waste Producer is Active. Once a Tier 2 is designated by the Authority an Active Waste Producer, their Service Requirements shall form part of the Services. For the avoidance of doubt, no Change Control Process is required where a Tier 2 Waste Producer becomes Active and such change is solely at the discretion of the Authority. Tier 3: Undefined/Pending Waste Producer(s) These are other Waste Producers who have similar Service Requirements to Tier 1 and 2 Waste Producers who are unknown / undefined at the Services Commencement Date and may be added during the Term following completion of the Change Control Process (Schedule 13 of Document 6 - Contract). Examples of Waste Producers covered within Tier 3 include, but are not limited to: Other GP sites not included within Tier 1 and Tier 2 (as set out in Clauses 5.5.1 and 5.5.2 in Document 5 Specification) due to other existing arrangements or insufficient data available to include within the Service Requirements. This is estimated to be <1% of all GPs in England. Community Pharmacy Influenza Vaccination Scheme waste, which responsibility for commissioning currently sits with the Waste Producer themselves. There are approximately 1700 Community Pharmacies offering this service. Home Patients waste, i.e. any waste generated by clinicians or the patient themselves in a residential setting (e.g. diabetes sharps, home based dialysis, virtual wards). This may be collected via other NHS premises (e.g. GP/ Community Pharmacy) or the patient’s own home. Any other NHS services provided by new or existing primary care sites (e.g. Enhanced Services, pop-up clinics/vaccine sites), which are introduced during the Term. The Successful Bidder will need to anticipate possible changes to Service Requirements as NHS services evolve and change over time. As a result of this procurement exercise, a separate contract (NHS Terms and Conditions for the Supply of Goods and Services) will be established with each Successful Bidder for each of the eleven (11) Lots as set out in table 1.7 of Document 1 ITT process overview’ (which can be found in the supplier documents folder | Salesforce for this opportunity). A contract for an initial duration of 6 years will be awarded with the option for the Contracting Authority in each instance to extend for a period or periods of up to a further 4 years (maximum contract duration of 10 years). Please note: Over the past few months, the Authority has been working on the service requirements, documentation, and process to ensure it reflects our service needs and meets the new Procurement Act 2023 (PA23). Consequently, please be aware that the documents published may differ from those previously published as part of our preliminary market engagement discussions and previous procurement process and Bidders MUST read all the attached documentation to understand the requirements, prior to completing the response documentation. For specific notice, a UK3 notice (Notice identifier) 2025/S000-056062 was published 28th August 2025. However, the procedure identified has been amended in this opportunity, from a Competitive Flexible Procedure to an Open Procedure. To register your interest and submit a bid, please follow the link below, and search for the project reference as detailed: https://health- family.force.com/s/Welcome Project Reference: C435895 Project Title Healthcare Clinical Waste Services for Primary Care: 11 Midlands NHS ICBs (2)

The Tender is to establish a Framework Agreement for the supply of Homecare Services ("Agreement"). The agreement will include the dispensing and delivery of Low, Mid and High Tech Homecare Services and Remote Patient Monitoring and Virtual Wards. The agreement will be split into four (4) lots: - Lot 1: Low Tech Homecare Services - Lot 2: Mid Tech Homecare Services - Lot 3: High Tech Homecare Services - Lot 4: Remote Patient Monitoring and Virtual Wards. The duration of the Agreement will be 4 years with no option to extend.

The contract is expected to initially be delivered for a period of 5 years, at a maximum total budget of up to £16,080,000 including VAT and £13,400,000 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years as well as the option to include other aspirational measures (which will be defined in the service specification) meaning the ceiling value has the potential to be higher. Due to the unknowns in advance of holding the premarket engagement session, it is currently expected that the extension value will be a 2 year pro rata of the core 5 year funding, estimated at £5,360,000 excluding VAT. This proposed extension value may also include pro rata funding of any additional aspirational measures invoked in the first 5 years of the contract. For example: If an aspirational annual requirement costing £500,000 per year is invoked in year 5, then the extension funding (if the aspirational measure is continued) will be the above figures plus the additional £500,000 per year. Further to this funding, the final specification will contain a list of aspirational measures which will be expected to be modified into the contract should the need and funding become available. The aspirational intent value, excluding the potential 2 year extension, is unknown at point of drafting this notice, so, an estimated value of £15,000,000 excluding VAT is applied to form the maximum total estimated value AT POINT OF DRAFTING THIS NOTICE. This aspirational intent has the potential to be invoked fully, partially, or not at all, and the Authority cannot guarantee that the successful supplier will be required to do any of the aspirational measures that will be listed in the final specification. The Healthcare Quality Improvement Partnership (HQIP) is seeking to procure the following services for the National Joint Registry (NJR). •NJR data management, solutions, statistical analysis and reporting, and (optional) associated services HQIP is not only looking for organisations to provide these services but also to partner with organisations that can demonstrate the following characteristics: •Strategic and solution orientated •Proactive, responsive and flexible •Ability to add value •Committed to continual improvement •Communicative and effective team player •Innovative Joint replacements have become common and highly successful operations that bring many patients improved mobility and relief from pain. Thousands of such operations take place in the UK every year. A wide range of implants can be used in joint replacement operations and the NJR helps to monitor the performance of these implants and the effectiveness of different types of surgery; improving clinical standards and benefiting patients, clinicians and the orthopaedic industry. The NJR was set up in April 2002 by the Department of Health (DH) and Welsh Government following a National Audit Office report into a failing ‘3M’ hip implant. From 1 April 2008, hosting arrangements for the NJR were transferred from the DH to HQIP. The NJR has collected hip and knee replacement data since April 2003, ankle replacement data since April 2010 and data for elbow and shoulder replacements since April 2012. The DH provided the initial start-up funding for the NJR. However, the system is now self-financing through a subscription charge on each ‘eligible’ hip, knee, ankle, elbow and shoulder implant which is payable by NHS Trusts (England), Health and Social Care Trusts (Northern Ireland), Local Health Boards (Wales) and independent (private) healthcare providers. The cost to the NHS was reduced in 2014 through a contributory financial subscription arrangement with the orthopaedic device industry whereby an annual subscription is charged for provision of the NJR Supplier Feedback service and other bespoke reporting. Since April 2014, the NJR subscription has been invoiced annually and the income managed in a dedicated fund at HQIP, governed by the NJR Board (NJRB). The purpose of the National Joint Registry, which covers England, Wales, Northern Ireland, the Isle of Man, the States of Guernsey and the Channel Islands, is to collect high quality and relevant data about joint replacement surgery in order to provide an early warning of issues relating to patient safety. In a continuous drive to improve the quality of outcomes and ensure the quality and cost-effectiveness of joint replacement surgery, the NJR will monitor and report on outcomes, and support and enable related research. The NJR’s strategic goals are to: •Monitor in real time the outcomes achieved by brand of prosthesis, hospital and surgeon, and highlight where these fall below an expected performance in order to allow prompt investigation and to support follow-up action. •Inform patients, clinicians, providers and commissioners of healthcare, regulators and implant suppliers of the outcomes achieved in joint replacement surgery. •Evidence variations in outcome achieved across surgical practice in order to inform best practice. •Enhance patient awareness of joint replacement outcomes to better inform patient choice and patients' quality of experience through engagement. •Support evidence-based purchasing of joint replacement implants for healthcare providers to support quality and cost effectiveness. •Support suppliers in the routine post-market surveillance of implants and provide information to clinicians, patients, hospital management and the regulatory authorities. Current Expectations - To be Defined Core service provision is expected to include: •Data systems and ingestion •Data processing and cleaning •Dynamic reporting and dashboards •Supplier feedback •Annual report statistical outputs •Outlier detection, reporting and analysis •PROMs and PREMs collection •Service desk and operational support Further details of the existing programme can be found at: https://www.njrcentre.org.uk/ For more information about this opportunity, please visit the eSourcing portal at: https://www.delta-esourcing.com/tenders/UK-UK-London:-Health-services./7449M9X8XA To respond to this opportunity, please click here: https://www.delta-esourcing.com/respond/7449M9X8XA

The contract is expected to initially be delivered for a period of 5 years, at a maximum total budget of up to £16,080,000 including VAT and £13,400,000 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years as well as the option to include other aspirational measures (which will be defined in the service specification) meaning the ceiling value has the potential to be higher. Due to the unknowns in advance of holding the premarket engagement session, it is currently expected that the extension value will be a 2 year pro rata of the core 5 year funding, estimated at £5,360,000 excluding VAT. This proposed extension value may also include pro rata funding of any additional aspirational measures invoked in the first 5 years of the contract. For example: If an aspirational annual requirement costing £500,000 per year is invoked in year 5, then the extension funding (if the aspirational measure is continued) will be the above figures plus the additional £500,000 per year. Further to this funding, the final specification will contain a list of aspirational measures which will be expected to be modified into the contract should the need and funding become available. The aspirational intent value, excluding the potential 2 year extension, is unknown at point of drafting this notice, so, an estimated value of £15,000,000 excluding VAT is applied to form the maximum total estimated value AT POINT OF DRAFTING THIS NOTICE. This aspirational intent has the potential to be invoked fully, partially, or not at all, and the Authority cannot guarantee that the successful supplier will be required to do any of the aspirational measures that will be listed in the final specification. The Healthcare Quality Improvement Partnership (HQIP) is seeking to procure the following services for the National Joint Registry (NJR). •NJR data management, solutions, statistical analysis and reporting, and (optional) associated services HQIP is not only looking for organisations to provide these services but also to partner with organisations that can demonstrate the following characteristics: •Strategic and solution orientated •Proactive, responsive and flexible •Ability to add value •Committed to continual improvement •Communicative and effective team player •Innovative Joint replacements have become common and highly successful operations that bring many patients improved mobility and relief from pain. Thousands of such operations take place in the UK every year. A wide range of implants can be used in joint replacement operations and the NJR helps to monitor the performance of these implants and the effectiveness of different types of surgery; improving clinical standards and benefiting patients, clinicians and the orthopaedic industry. The NJR was set up in April 2002 by the Department of Health (DH) and Welsh Government following a National Audit Office report into a failing ‘3M’ hip implant. From 1 April 2008, hosting arrangements for the NJR were transferred from the DH to HQIP. The NJR has collected hip and knee replacement data since April 2003, ankle replacement data since April 2010 and data for elbow and shoulder replacements since April 2012. The DH provided the initial start-up funding for the NJR. However, the system is now self-financing through a subscription charge on each ‘eligible’ hip, knee, ankle, elbow and shoulder implant which is payable by NHS Trusts (England), Health and Social Care Trusts (Northern Ireland), Local Health Boards (Wales) and independent (private) healthcare providers. The cost to the NHS was reduced in 2014 through a contributory financial subscription arrangement with the orthopaedic device industry whereby an annual subscription is charged for provision of the NJR Supplier Feedback service and other bespoke reporting. Since April 2014, the NJR subscription has been invoiced annually and the income managed in a dedicated fund at HQIP, governed by the NJR Board (NJRB). The purpose of the National Joint Registry, which covers England, Wales, Northern Ireland, the Isle of Man, the States of Guernsey and the Channel Islands, is to collect high quality and relevant data about joint replacement surgery in order to provide an early warning of issues relating to patient safety. In a continuous drive to improve the quality of outcomes and ensure the quality and cost-effectiveness of joint replacement surgery, the NJR will monitor and report on outcomes, and support and enable related research. The NJR’s strategic goals are to: •Monitor in real time the outcomes achieved by brand of prosthesis, hospital and surgeon, and highlight where these fall below an expected performance in order to allow prompt investigation and to support follow-up action. •Inform patients, clinicians, providers and commissioners of healthcare, regulators and implant suppliers of the outcomes achieved in joint replacement surgery. •Evidence variations in outcome achieved across surgical practice in order to inform best practice. •Enhance patient awareness of joint replacement outcomes to better inform patient choice and patients' quality of experience through engagement. •Support evidence-based purchasing of joint replacement implants for healthcare providers to support quality and cost effectiveness. •Support suppliers in the routine post-market surveillance of implants and provide information to clinicians, patients, hospital management and the regulatory authorities. Current Expectations - To be Defined Core service provision is expected to include: •Data systems and ingestion •Data processing and cleaning •Dynamic reporting and dashboards •Supplier feedback •Annual report statistical outputs •Outlier detection, reporting and analysis •PROMs and PREMs collection •Service desk and operational support Further details of the existing programme can be found at: https://www.njrcentre.org.uk/ For more information about this opportunity, please visit the eSourcing portal at: https://www.delta-esourcing.com/tenders/UK-UK-London:-Health-services./7449M9X8XA To respond to this opportunity, please click here: https://www.delta-esourcing.com/respond/7449M9X8XA

This is a Framework for the provision of Endoscopy Consumables, including but not limited to, Capsule Endoscopy, Diagnostic & Biopsy Tools, Catheters & Balloon Catheters, Dilators, Endoscopic Clips & Needles, Electrosurgical & Endoscopic Probes, Polypectomy, Retrieval & Resection Devices, Guidewires, Endoscopic Markers & Dyes, Stents & Stent Accessories, Endourology Consumables and Endoscopy Accessories.

The Contracting Authority is procuring the NHS Healthier You Programme utilising the competitive provider selection process under the Health Care Services (Provider Selection Regime) Regulations 2023. This competitive provider selection process has multiple gateways as described in this notice. <br/><br/>The NHS Healthier You Programme procurement comprises of the following:<br/>• NHS Healthier You Behavioural Support for Obesity Prescribing ("BSOP) Service"): Targeted support for individuals prescribed pharmacotherapy GLP-1 medications as approved in a Primary Care setting by NICE. Service Users provided with the BSOP Service are referred to as the "BSOP Cohort".<br/>• NHS Healthier You Diabetes Prevention Programme ("DPP Service"): Support for individuals identified as at high risk of developing type 2 diabetes. Service Users provided with the DPP Service are referred to as the "DPP Cohort". <br/>• NHS Healthier You Type 2 Diabetes Path to Remission ("T2DR Service"): Support for individuals diagnosed with type 2 diabetes within the last 6 years and living with overweight or obesity. Service Users provided with the T2DR Service are referred to as the "T2DR Cohort".<br/>• NHS Healthier You Long Term Conditions Prevention Pilot ("LTCP Service"): Support for individuals diagnosed with hypertension. Service Users provided with the LTCP Service are referred to as the "LTCP Cohort".<br/><br/>The Contracting Authority has divided this opportunity into 26 ICB/ICB Clusters. ICB Clusters are groupings of ICBs. The complete list is set out in VI.3.<br/><br/>Bidders will need the capability and capacity to provide the full suite of services to an ICB/ICB Cluster, offering eligible participants a choice of group based in-person services or a digitally delivered, independently accessed service provided through a web browser or a mobile application. The Type 2 diabetes Path to Remission intervention will only be delivered on a one-to-one basis (delivered in-person or remotely).<br/><br/>Contracts will be awarded by Supplier. Bidders can be awarded a contract for more than one ICB/ICB Cluster. In such instances, one contract would be issued to the Supplier listing the ICB's/ICB Clusters awarded. This means a maximum of 26 contracts may be awarded in the event a different Supplier is awarded for each ICB/ICB Cluster.<br/><br/>The anticipated value across the ICB's/ICB Clusters is £386,000,000 excluding VAT. This is based on the initial term of 36 months. There will be an option to extend by up to 24 months, giving a maximum term of 60 months. The anticipated value of the 60 month term is £738,000,000 excluding VAT. VAT will be applied as appropriate.<br/><br/>The estimated date of mobilisation / service commencement will be from 1 November 2026.

NHS England Specialised Commissioning (the "Contracting Authority”) is inviting suitably qualified and experienced suppliers to express an interest in providing Positron Emission Tomography – Computed Tomography (PET-CT) Services (all ages) and/or supplying the Tracers to providers of the Services, by responding to this opportunity. NHS Arden and Greater East Midlands CSU (AGCSU) is acting as an agent for and on behalf of the Contracting Authority and is supporting the ITT. PET-CT is a specialist diagnostic scan which is used extensively in cancer; it is also used in a relatively small number of other non-cancer specialties, such as neurology and infection and immunity. The scan itself involves the use of radioisotopes (or ‘tracers’) which are injected into the patient around an hour prior to the scan. Tracers can be grouped into those which are produced in cyclotron and hot cell facilities (‘standard tracers’), and those which typically need to be produced in radiopharmacy facilities that are co-located with scanners, due to radioactive half-life considerations (‘non-standard tracers’). Standard tracers account for >90% of PET-CT activity and almost all standard tracer scans involve FDG (a tracer). The single procurement opportunity will comprise two lots: Lot 1 - Scanning Services, including the optional supply of Gallium Non-Standard Tracers (NSTs) (the option will be procured by way of variant tenders as explained further below); and Lot 2 – Supply of Standard Tracers (STs). Each Lot will comprise of 12 identical Sub-Lots, enabling the pairing of Lot 1 and Lot 2 suppliers so that a complete PET-CT service is available to patients within those 12 Sub-Lot areas. On completion of the procurement, there will be 12 scanning services, which will together equate to c.50% of the NHS PET-CT market in England. The opportunity also includes a variant bid element within Lot 1, which will allow bidders to put forward proposals to establish up to 6 gallium scanning services nationally, i.e., 1 per NHS England Region included within the procurement opportunity. This is to enable increased access for patients to gallium scans. It is also proposed to future-proof the provision of amyloid scanning – this will only be activated within the Contracts in the event that approval is given for the use of disease modifying treatments for memory loss conditions and that those treatments require PET-CT amyloid scanning. This step has been taken to futureproof the Contracts for a potential, but not certain, service development. Form of contracts: The contracts to be entered into will be: Lot 1 - Scanning Services: Contracts will be entered into on the form of the NHS Standard Contract 2026/27. Where gallium is to be supplied as part of a consortium, the Contracting Authority will mandate a form of 'sub-contract' for use between the scanning services provider and the gallium supplier. Lot 2 - Standard Tracer Supply: Contracts will be entered into on the form of a bespoke supply of goods contract (as the NHS Standard Contract is not appropriate for a supply of goods contract). The form of contract will be mandated as a sub-contract between the scanning services provider in the relevant geography in Lot 1 and the standard tracer supplier in the corresponding geography in Lot 2. This model has been used previously to secure PET-CT provision. Direct Agreements – The Contracting Authority will also enter into a direct agreement with the successful standard tracer suppliers (to ensure proper flow down across all contracts linked to the procurement opportunity). Open procedure description: This procurement will follow an Open Procedure. This will be a single stage procurement where Bidders are asked to submit a response to the PSQ and ITT on the same date. Only bidders that pass the PSQ will have their tender response evaluated. No additional steps will be used. Following publication of this Tender Notice, bidders will be required to complete an EWA before receiving access to the Invitation to Tender (ITT). Completion of these will be a gateway requirement for access to the ITT, and bidders must submit their completed EWA within the timescales set out in this Tender Notice. Following confirmation of compliance, the ITT will be released simultaneously to all eligible bidders (see below) in early March 2026. Indicative procurement timeline (which is subject to change at NHSE’s discretion): • Tender Notice publication: 18/02/2026 • Access provided to EWA : 18/02/026 • Deadline for submission of EWA : 4/03/2026 • PSQ and ITT issued to all eligible bidders (see below): early March 2026 • Clarification question period deadline: mid-May 2026 • Final clarification question log issued: mid to late May 2026 • PSQ and ITT submission deadline: early June 2026 Eligible bidders are bidders who have received confirmation from NHSE that their submitted EWA has been counter-signed. Please allow approximately four (4) working days for the Contracting Authority to process your submission and confirm eligibility. The Contracting Authority may consider allowing late submission of the EWA , however in no circumstances can bidders submit this documentation after 06/03/2026 at 12:0hrs. Bidders who are late to submit their EWA documents will be required to submit their PSQ and ITT responses on the same date as bidders who submit their EWA documents on time. The PSQ will be assessed on a pass/fail basis covering legal, financial and technical requirements. Tenders from bidders that pass all PSQ criteria will then be evaluated. Bidders who fail the PSQ will be excluded and will not have their tenders evaluated. A clarification process will operate during the PSQ and ITT period to enable bidders to seek clarification from the Contracting Authority. Due diligence will be undertaken by the Contracting Authority prior to contract award to provide assurance that there are no material risks that could prevent contract signature i.e. if a Supplier bidding for the contract no longer meets the minimum standards required, and their Tender is rejected as a result, the Contracting Authority reserves the right to award the Contract to the next highest scoring Supplier. Please note the Contracting Authority reserves the right at any stage of the procurement to abandon the competition and not award a contract. The Contracting Authority also reserves the right to make minor amendments to the procurement documentation (for example, to clarify or refine requirements), provided such changes are not substantial and do not distort competition. If amendments are made, the Contracting Authority will consider whether any corresponding tender deadlines require revision and will issue updated documentation or notices where appropriate.

Overview of Requirement University Hospital Southampton NHS Foundation Trust (UHS) is initiating the re-procurement process for its Imaging Infrastructure Support Service (IISS). As a large, specialised acute teaching trust, UHS manages a diverse and complex imaging estate including MRI, CT, X-Ray, Ultrasound, Echo, Angiography, and Fluoroscopy supporting 24/7 clinical pathways. The current contract, which provides a comprehensive managed service, is approaching expiry. Purpose of the Engagement This Preliminary Market Engagement (PME) is a critical step in developing the Trust's Business Case. The objectives for the engagement are to: - Gather insight on current capabilities, innovations, and delivery models. - Test and shape the Trust's emerging requirements and procurement strategy. - Understand supplier perspectives on risk, contract structure, and performance expectations. - Encourage broad and competitive participation in the forthcoming procurement. Scope and Model Neutrality The Trust is seeking information on a broad range of high-level service models. At this stage, UHS has not yet committed to a specific commercial structure. The engagement aims to understand the pros and cons of: - Fully managed equipment service models. - Hybrid or shared-responsibility models. - Strategic partnerships involving mixed-vendor and mixed-age estates. - Other models used globally. Supply and Delivery Expectations This notice is for pre-procurement consultation only. The Trust invites input from Original Equipment Manufacturers (OEMs), Managed Service Providers (MSPs), and technical advisors. The engagement will involve a period of active discovery, including Requests for Information (RFIs) and 1-to-1 sessions. Out of Scope To maintain the integrity of the future formal procurement, the following are strictly out of scope for this PME: - Detailed pricing or firm cost benchmarks. - Final contract terms or specific risk transfer mechanisms. - Supplier-specific solution designs or evaluation/scoring criteria.

This framework proposal encompasses three distinct lots, each addressing a key area of the employee lifecycle. Lot 1a focuses on Applicant Tracking Systems, providing tools to streamline recruitment processes, manage candidate pipelines, and improve hiring efficiency. Lot 1b covers Onboarding solutions, aiming to facilitate seamless integration for new hires through automated workflows and compliance management. Lot 1c addresses Employee Screening, offering services and technologies to ensure thorough background checks and verification, supporting organisational risk mitigation and regulatory adherence. Collectively, these lots are designed to enhance HR operations and ensure a robust workforce management strategy.

Lot 2a covers programmes that enable employees to sacrifice a portion of their salary in exchange for a range of benefits. These schemes are designed to provide tax and National Insurance savings for both employees and employers. Typical benefits may include pension contributions, childcare vouchers, cycle-to-work schemes, and other perks that enhance overall employee wellbeing and retention. Lot 2b focuses on car leasing services, with an emphasis on electric vehicles (EVs) and related infrastructure such as car charging solutions. The lot aims to facilitate environmentally friendly commuting options for employees by offering flexible leasing arrangements, access to EVs, and support for installation and management of charging points. This supports sustainability goals and promotes the adoption of greener transport alternatives.

The procurement encompasses five distinct lots within the Learning and Development framework: Lot 3a provides mandatory clinical training for healthcare professionals, such as infection prevention, safeguarding, and basic life support; Lot 3b delivers professional development opportunities for all staff, including leadership, management, and specialist skills; Lot 3c ensures mandatory non-clinical training, covering health and safety, GDPR, equality and diversity, and fire safety; Lot 3d offers a managed service with a Learning Management System (LMS) to facilitate booking, tracking, and management of training records; and Lot 3e focuses on training assessment, conducting needs analysis, evaluating effectiveness, and providing feedback to optimise future programmes and align learning with organisational goals.